Biotechnology firm DiscoverX has launched new cell-based assays platform for confirmation of compound-target engagement in drug discovery.
The company claims that the InCELL Pulse target engagement platform offers scientists with the ability to generate their own cell-based target engagement assays to confirm compound cell entry and target binding in the native cellular environment.
Cellular drug penetration monitoring and drug target interaction can let scientists assess the compound on-target potency and confirmation of mode of action. At present, the platforms offering bio-chemical or cell-based targets are limited, according to DiscoverX.
The platform makes it easy to confirm compound cell entry and target binding, validate hits identified in biochemical assays, measure cellular EC50 values and rank compound potency.
DiscoverX says that the cellular binding assays need no custom chemical tracer or antibody reagents and offer a convenient and easy-to-use protocol for a chosen target.
DiscoverX commercial operations senior vice president Theresa Schaub said: "With the addition of the InCELL Pulse target engagement assays to our current target engagement portfolio, our customers now have complete control to develop their own cell-based binding assays, a capability many researchers need due to the unique compounds and targets that aren't offered by commercially available assays."
InCELL Pulse target engagement assays allow to rapidly create target engagement cell-based assays in less than 2 weeks after cloning.
DiscoverX CEO Todd Nelson said: "Now customers can easily confirm compound cell entry and measure compound binding to their protein target in the native cellular environment even when functional assays are difficult or unavailable.
“DiscoverX remains committed to providing solutions and platforms for our customers to easily generate biologically relevant data for more confident drug discovery decisions."